This was a 25% increase in the number of dollars invested over the same period last year. The money was spread of 738 deal, which is approximately the same as last year.

This represents a return to the pre-recession levels. The CB Insights “left it to others to decide whether that represents a return to normalcy or an untenable VC investment bubble.”

Join us to hear how experienced deal-makers are succeeding, at our upcoming webinar:

Conference Preview: Successful Deal-making with Small Companies April 21, 2011, 11:00am EST.

We’ll be discussing relationship building, cross-cultural appreciation, ongoing consulting, and step-wise deal structures, among other topics. We’ve gathered representatives from both the small and big company perspectives to share their thoughts — tune in to learn how you can hasten and improve your own deal process.

Webinar speakers:

April’s webinar is an exclusive preview of a live panel discussion to be held at yet2.com’s upcoming Open Innovation conference in May, in Boston.

Register today for the Successful Deal-making with Small Companies Preview Webinar here:

https://www2.gotomeeting.com/register/311188682

PS  Previously, our speakers have included; Dean Kamen, Dr. Oz, Henry Chesbrough, Esther Dyson, etc.

The event is an intimate technology scouting and networking conference for executive Open Innovation, technology, R&D, licensing, and business leaders. Recent conferences have averaged 120–140 leaders representing 100+ global corporations from six continents. Big enough to be global, small enough to encourage meaningful conversation.

This year the event will be held May 17-19th at the Hyatt Regency Cambridge, MASS USA.

Speakers include:

Dr. Kenneth W. Klimpel, Worldwide Director – External Innovation, Colgate Palmolive, Stephen J. Baggott, Director, Global Business Development, Procter & Gamble, Jim Toth, PhD, Sr. Director of Technology Strategy, Tyco Electronics, Marcel Lubben, Managing Director, DSM Venturing and DSM Licensing, and Michael T. Kane, Founder, Fairbridge Venture Partners.

Past attendees include: Agfa, Amway, Ashland, AT&T, Bayer, BP, Catepillar, Ciba, DSM, DuPont, Eastman Chemical, GE, Georgia-Pacific, W.L. Gore, Honeywell, IBM, Microsoft, NASA, Northrop Grumman, P&G, Royal Dutch Shell, Samsung, SAP, Tyco,Unilever, Wrigley.

A complete list of speakers and past attendees can be found here.

New Study Catalogues Evidence for Probiotic, Bacillus coagulans

Review paper supports multiple health claims for specific Bacillus coagulans strain, GanedenBC30®

Cleveland (PRWEB) January 25, 2011

A new paper examining recent research and safety data published in the peer-reviewed journal Food Science and Technology Bulletin provides scientific support for Bacillus coagulans as a probiotic. The overview supports the use of probiotics in general and discusses a specific Bacillus coagulans strain, known as GanedenBC30 (Bacillus coagulans GBI-30, 6086), manufactured by consumer healthcare company Ganeden Biotech, for its probiotic attributes. The study summarizes how GanedenBC30 supports its health claims related to safety, gastrointestinal health, immune health, joint health and includes never before published data.

“Probiotic strains have been traditionally limited to Lactobacillus and Bifidobacterium,” explained Dr. Glenn Gibson, one of the world’s leading probiotic experts and co-author of the paper. “The evaluation of this recent data shows great promise for Bacillus coagulans as a new type of probiotic that’s come to the forefront.”

Probiotics, or “beneficial bacteria,” have been shown to improve digestive health and boost immunity. The challenge for many probiotic strains has always been survivability through harsh stomach acids in order to arrive in the intestines where they can have the greatest digestive health benefit. Bacillus coagulans based strains of probiotics have a distinct advantage since they form a naturally occurring layer of organic material that helps protect the delicate genetic core of the probiotic. Conventional probiotics such as Lactobacillus and Bifidobacterium are unable to form this protective shield, making them more vulnerable.

“Bacillus coagulans behaves in a totally different way than many common probiotic strains today due to its spore-forming nature,” Gibson, who is also the professor of microbiology at Reading University, England, commented. “This exciting development in probiotic technology could very well lead to seeing Bacillus coagulans probiotics like GanedenBC30 showing up in more products due to its hearty nature.”

Highlights of the research data review of GanedenBC30 include relieving abdominal pain and bloating in IBS sufferers, showing a potential to digest protein, lactose and fructose, positively affecting the immune system, protecting against two strains of influenza, decreasing joint pain and improving mobility in rheumatoid arthritis sufferers, and surviving through a simulated gastric environment. The safety data reviewed seven tests and revealed no safety issues even when GanedenBC30was consumed in high quantities.

GanedenBC30 is the probiotic included in Digestive Advantage® and Sustenex® products which have already been demonstrated safe and effective in clinical trials. GanedenBC30 can also be found as an added ingredient in over 45 functional foods and beverages, including bread, nutrition bars, instant soup mix, hot tea, ice cream, and frozen yogurt.

About Ganeden Biotech

Founded in 1996, Ganeden Biotech is a privately held company based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the United States through its Digestive Advantage and Sustenex brands. It also licenses its patented probiotic bacteria, GanedenBC30, for use in commercial food and beverage applications as well as in medical foods and dietary supplements. For more information on Ganeden Biotech, GanedenBC30 or this recent study, visit ganedenlabs.com.

Tokyo, Japan and Boston, MA USA, 24 January 2011 — yet2.com has formed yet2Ventures, a fund created to help Fortune 500 firms and other owners of venture capital investments drive value in their portfolio companies. We can provide follow-on investment and liquidity to help small companies grow. We are excited about this effort and believe yet2.com is uniquely positioned to help portfolio companies grow with:

• Our global network, with offices in Tokyo, Boston, Liverpool, and Wilmington
• Our IP experience
• Our technology licensing experience
• And, now our capital

Venture funding is an excellent fit with the established yet2.com market, where we help large and small companies connect on new and robust technologies.

Our first joint investment with JAIC is in Avantis Medical Systems of Sunnyvale, California. They develop and manufacture catheter-based endoscopic devices for detecting and treating cancer in the GI tract.

The yet2Ventures fund is a good partnership opportunity for VC firms and other strategic investors. Perhaps we can help your portfolio grow, too? Please contact us at:venturefund@yet2.com.

About JAIC

Japan Asia Investment Co., Ltd. (JAIC) is an independent venture capital company founded in 1981 by the Japan Association of Corporate Executives (Keizai Doyukai). JAIC’s operations are centered on three geographic hubs — Japan, Asia, and the United States. In these regions, JAIC provides financial support for companies in various stages of development from promising venture enterprises to companies with succession or business reorganization needs, or firms looking to revitalize their businesses. In addition, JAIC seeks to stimulate growth and raise the corporate value of invested companies by providing support on the management side as well. These include supplying information, consulting for initial public offerings (IPO), and business matching.

About yet2.com

yet2.com provides intellectual property consulting and licensing services to world-class clients around the globe. Yet2.com Inc and its online marketplace were founded in 1999 to promote Open Innovation, with original investments from Siemens, Bayer, Honeywell, DuPont, Procter & Gamble, Caterpillar, and NTT Leasing. The privately held company has offices in the United States, Europe, and Japan. The web site now has over 120,000 registered marketplace users including many of the Fortune 500 and over 16,000 smaller technology companies. In addition to its core team, yet2.com has created a wide network of Open Innovation partners covering many of the technology-rich countries around the world as well as relationships with open innovation organizations, technical expert networks, SME networks, technical magazines, online technical communities, and technology brokers. These provide market-wide access to technologies and needs in countries such as Russia, China, India, Korea, Brazil, South Africa, Japan, the US, and the EU. For more information, visit www.yet2.com or contact Tim Bernstein 1-781-972-0600.

We’re seeking innovative technologies in 4 categories for yet2.com’s new Step2Change Technology Competition. Finalists receive promotional services as well as presentation opportunity to 100+ senior executive technology scouts from the Global 1000!

In partnership with NASA Tech Briefs, Clean 15, RadTech and yet2 Ventures, the competition is designed to connect exciting technology companies in four leading areas to the commercial market: 1) Sustainable Packaging; 2) Materials—lighter/stronger/better/cleaner; 3) Consumer home/health medical devices; and 4) Electronics.

yet2.com’s Step2Change Technology Competition is organized in conjunction with yet2.com’s annual Executive Briefing conference, to take place in Boston in May, 2011.

Competition finalists will gain ACCESS TO:
• Unparalleled Cross-section of the Global 1000 International Partners and Markets
• Sources of Capital
• Joint Ventures/Licensing Opportunities
• Increased Deal Flow

Our goal is to connect leading edge technologies to the partners and capital necessary to accelerate their access to the global market.
Submissions due March 15, 2011!

Let us connect you! Don’t miss this unique access to the Global 1000!

Learn more and apply here!

Governments are key drivers of product innovation. Funding from the American Recovery and Reinvestment Act of 2009 (ARRA), for instance, is helping governments try out innovative products on infrastructure projects, such as advanced materials for pavement rehabilitation and improved sensors for smart electric grids, reports Popular Mechanics.

Boston-based yet2.com, a company that operates an online technology marketplace and provides intellectual property consulting and licensing services, has assisted governments in finding innovative products.

Tim Bernstein

“We’ve done several searches on behalf of government organizations — everything from anti-graffiti technologies for municipal transportation departments to fairly advanced military applications for the federal military,” says Tim Bernstein, yet2.com’s chief operating officer.

Bernstein’s firm has helped client technology companies close several deals based on yet2.com’s technology searches. Yet2.com’s clients include manufacturers that represent more than 40 percent of the world’s R&D capacity.

Yet2.com’s online technology marketplace lists a variety of public sector technology needs, including a need for safe efficient water treatment and a need to generate biodiesel from waste fuel. Here’s an example (with description) of a product in the yet2.com online technology marketplace that is applicable to the public sector:

DuPont Premium Playground and Landscape Mulch

The product can mimic wood mulch or take on novelty colors or shapes. Its cushioning properties meet or exceed ASTM standards for playground use.

DuPont has developed a polymer mulch suitable for playground and horticultural applications. Until now, natural or synthetic mulches have presented one or more disadvantages such as short life, possible presence of contaminants like metal fibers, easy displacement, unpleasant odor, and the ability to support fungus growth. The DuPont polymer mulch is long lasting and will not fade or rot. It is also completely contaminant free, with no risk of any metallic fragments, as occasionally found in shredded tire rubber mulches. Additional advantages over rubber mulch are its consistent, uniform appearance, no unpleasant odor and through-thickness color for long-term color retention. The mulch can be manufactured in a variety of colors, shapes and novelty decorative patterns, making it particularly attractive for playground applications. It also can be given a bark-like appearance for garden use.

Yet2.com hosts its 11th Executive Briefing — Open Innovation: Making a Step-Change Impact in Boston from May 17-19, 2011. It is a gathering where attendees can meet thought-leaders, decision-makers, and practitioners who are doing technology deals for their organizations. Specific location and details will be announced soon.

A-CUBE Inc. and Wakunaga Pharmaceutical Co., Ltd. Announce Agreement on a Monoclonal Therapeutic Antibody

WAKUNAGA will develop and validate animal models of various cancers using standard-of-care treatments, as well as develop and validate bioanalytical assays. At this point, the in vivo therapeutic potential of the two sets of monoclonals will be evaluated by WAKUNAGA. WAKUNAGA has the exclusive rights to conduct this evaluation in cancer models, and to negotiate for, and enter into exclusive collaborative research agreement with A-CUBE during a six month period following the experimental evaluation. Financial terms of the agreement were not disclosed.

“We are very pleased with this agreement with WAKUNAGA who have state-of-the art R&D facilities and expertise,” said Nobu Ota PhD, Founder and President of A-CUBE. “c-MET is a strong molecular target for cancer treatment.” Dr. Ota added, “WAKUNAGA is an excellent partner for these studies, and we have developed a strong relationship between our teams.”

A-CUBE is a venture capital backed company, supported by JAIC and yet2.com venture funds, that uses proprietary in silico algorithms to predict and monetize novel drug targets related to blockbuster drugs. It has used this to develop a preclinical therapeutic monoclonal antibody for cancer which has been partnered. It also has a therapeutic monoclonal antibody for eye diseases and various DNA vaccine programs.

“We had developed expertise in animal cancer model for evaluation of Epidermal Growth Factor and its antibody. We believe that this collaboration with A-CUBE will be the ideal opportunity for us to expand our research field into new area,” said Mr. Hironobu Wakunaga, Director of R&D division of WAKUNAGA.

WAKUNAGA was founded in 1955 and has its head office in Osaka, Japan. It is one of the medium-sized pharmaceutical companies in Japan in OTC formulations of pharmaceuticals from herbal extracts. Its affiliate, Wakunaga of America Co., Ltd. (Mission Viejo, CA), markets dietary supplements and OTC drugs worldwide.

For some years, WAKUNAGA has been expanding its R&D division into molecular diagnostics area for providing the HLA typing reagents to the Japan Marrow Donor Program. The division has also been concentrating on the prescription drug sector, especially in antibiotics with a strategy of out-license after discovery. WAKUNAGA has global licensing agreements with several pharmaceutical companies.

For further information, please see http://www.wakunaga.co.jp/english/index.html.

JAIC America is a venture capital firm based in the Silicon Valley focused on early stage investments in the Mobile/Communications, Digital Media, Life Science and Cleantech sectors. JAIC is part of Japan Asia Investment Co. (JAIC) group, a premier venture capital and private equity firm listed on the Tokyo Stock Exchange with $1.3 billion assets under management. JAIC America was established in January 1999 and since then, we have actively invested in the U.S. JAIC has successfully created several U.S.-Japan cross-border business models and have the know-how to bring U.S. technologies, services, and business models to Japan. JAIC tries to keep the right “management team-investor” balance to engender a productive outcome. We know when we add value and when we impede progress. For more information, visithttp://www.jaicamerica.com.

yet2.com provides intellectual property consulting and licensing services to world-class clients around the globe. Yet2.com Inc. and its online marketplace were founded in 1999 to promote Open Innovation, with original investments from Siemens, Bayer, Honeywell, DuPont, Procter & Gamble, Caterpillar, and NTT Leasing. The privately held company has offices in the United States, Europe, and Japan. The web site now has over 120,000 registered marketplace users including many of the Fortune 500 and over 16,000 smaller technology companies. In addition to its core team, yet2.com has created a wide network of Open Innovation partners covering many of the technology-rich countries around the world as well as relationships with open innovation organizations, technical expert networks, SME networks, technical magazines, online technical communities, and technology brokers. These provide market-wide access to technologies and needs in countries such as Russia, China, India, Korea, Brazil, South Africa, Japan, the U.S., and the EU. For more information, visit www.yet2.com or contact Tim Bernstein, 1-781-972-0600.

CONTACT:  A-CUBE, Inc.
          Nigel Ten Fleming PhD, Chief Executive Officer
          (415)-515-7614
          Nigel@ACUBEinsilico.com

Electro Petroleum (EPI) hired yet2.com 3 years ago.  We were so impressed with them that yet2Ventures invested.  Now EPI has investors, route to market partners, customers and is seeing real success turning dormant oils wells into productive ones.

How did this happen?

The Market

2/3 of the world’s heavy oil is to viscous to pump.  In fact there is more oil in the Canadian Oil Sands than all of the Middle East combined.  The problem is that it’s to heavy to pump.  The technology of choice was to ‘steam’ a well, meaning pump steam down a well, then pump up the oil/water mixture.  However this requires a lot of energy to steam water and to pump it down the well.  Steam condenses below about 2,000 feet, so in addition to all of the other major drawbacks, this approach doesn’t work when the oil is deep.

The Technology

Electro Petroleum uses a patented technology called EEOR – Electrically Enhanced Oil Recovery^SM.  The electrical field upgrades the heavy crude through an electro-chemical process, mobilizes it through electro-kinetics, and heats it through joule or resistance heating .  Here’s a neat explanation of the technology. with a video.

What does all of this cost?  $4/barrel.

The Solution

What did yet2.com do?  We worked closely with the CEO of Electro Petroleum, Phil Bell.  We introduced him to Fortune 500 companies to help vet the technology.  We found capital sources to invest.  We found oil fields who wanted to be customers, like Deloro.  After all of this, we invested too.

Now Elecro Petroleum has wells producing that were abandoned.  The first is owned by Deloro, and it’s producing more than 15 barrel per day.  Other wells are in the process and looking very positive.

The Passion

We love helping entrepreneurs like Phil Bell, commercialize their technology.  We love helping entrepreneurs find; partners, customers, capital and people.  If you have an impressive technology we’ll love helping you too.

Publications:

Wittle JK and Hill DG, Use of Direct Current Electrical Stimulation for Heavy Oil Production, Society of Petroleum Engineers Applied Technology Workshop – Technologies for Thermal Heavy Oil and Bitumen Recovery and Production, Calgary, Alberta, Canada, March 14–15, 2006.
Wittle JK and Hill DG, Direct Current Electrical Stimulation – A New Approach to Enhancing Heavy Oil Production, First World Heavy Oil Conference, Beijing, China, November 12–15, 2006.

Wittle JK, Hill DG, and Chilingar GV, EEOR – Electrically Enhanced Oil Recovery^SM Using Direct Current, Oil Sands Heavy Oil Technologies Conference, July 18-20, 2007.

Wittle JK, Hill DG, and Chilingar GV, SPE-114012, Direct Current Electrical Enhanced Oil Recovery in Heavy-Oil Reservoirs To Improve Recovery, Reduce Water Cut, and Reduce H2S Production While Increasing API Gravity, presented at the 2008 SPE Western Regional and Pacific Section AAPG Joint Meeting, Bakersfield, California, USA, March 31–April 2, 2008.

Recent Deloro Press Release:

Vancouver, BC, November 04, 2010 — Deloro Resources Ltd. (TSX-V DLL) (“Deloro”) is pleased to announce that the new well, Deloro Cathkin DD-7a2-25-3D15-24-38-20 successfully penetrated the McLaren oil formation at its Wilkie, SK project, estimated to contain 63,000,000 BBL of heavy oil. The McLaren formation surrounding the wellbore was stimulated with DC current for several weeks, and production was commenced in mid-October. After several days of testing it became apparent to our engineers that any oil production was being overpowered by water production to a degree indicating that a water zone adjacent to the oil zone had inadvertently been penetrated. Deloro and EPI engineering staff are confident that the issue will be corrected with further down-hole work designed to allow this well to become the Joint Venture’s second producing heavy oil well at Wilkie.

The Pilot Test well (117.3A2-25-3D 10-24-38-20) has been producing continuously with minor mechanical disruptions since late September. Daily production has ranged between 15 and 55 BBL and averages approximately 30 BBLs per day. Our technical advisors are anticipating an increase in the average daily production going forward as the equipment, pressure and flow rates are adjusted. Several shipments of oil have been made, the proceeds of which are forwarded to EPI in order to repay the cost of re-working and re-configuring the well in September.

Now that commercial oil production has been achieved at Wilkie, the Management of Deloro Resources is confident that EPI’s EEOR technology can be deployed on all of the wells contemplated on the remaining leases. Furthermore, the company’s business model of acquiring and developing production from known heavy oil reservoirs that were previous deemed non-recoverable or “stranded” is sound.

For more information please contact:

Deloro Resources Limited

Mike Magrum, P.Eng.
President and Director
604-484-5761: Vancouver Office
877-454-0383: For more information, Mark Tommasi